<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Computer Science</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A179E2C-FB5E-4836-AA80-6301F4DD5AB6"><gtr:id>4A179E2C-FB5E-4836-AA80-6301F4DD5AB6</gtr:id><gtr:name>University of Sydney</gtr:name><gtr:address><gtr:line1>University of Sydney</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5FC2511-03F1-4AC0-9C83-DE14AEA0FFDE"><gtr:id>D5FC2511-03F1-4AC0-9C83-DE14AEA0FFDE</gtr:id><gtr:name>Swiss Federal Inst of Technology (EPFL)</gtr:name><gtr:address><gtr:line1>Station 15</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F18FA757-E0BF-4938-85FF-F1FF1DE55D4B"><gtr:id>F18FA757-E0BF-4938-85FF-F1FF1DE55D4B</gtr:id><gtr:name>Philips Healthcare</gtr:name><gtr:address><gtr:line1>Philips Centre, Guildford Business Park</gtr:line1><gtr:postCode>GU2 8HX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/59B08208-1FCC-46DA-8DCA-77C47302D4D5"><gtr:id>59B08208-1FCC-46DA-8DCA-77C47302D4D5</gtr:id><gtr:firstName>Eleftheria</gtr:firstName><gtr:surname>Panagiotaki</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FN021967%2F1"><gtr:id>6A6149EE-4FBF-4D2F-B892-FB7AC1C17155</gtr:id><gtr:title>Non-invasive MRI Biomarkers for Oncology</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>EP/N021967/1</gtr:grantReference><gtr:abstractText>This project develops innovative Magnetic Resonance Imaging (MRI) methods to reveal new non-invasive markers of cancer pathology. In particular the research programme develops biophysical models of tumour tissue that support non-invasive estimates of key characteristics of tissue cellular architecture including those that currently guide diagnosis, grading, and treatment assignment through classical histology. These cellular characteristics include cell size, cell shape, cell density, similar features of subcellular structures, and potentially new features that histology cannot reveal such as cell membrane permeability and cell cytoplasm viscosity. In contrast to classical histology, such an approach avoids unnecessary interventions like biopsies. Moreover, the models combine with macroscopic imaging to provide maps of histological features over the whole organ, thus evading false-positives from poor biopsy targeting. In contrast to current imaging techniques, the new model-based imaging techniques provide much greater specificity associating contrast with particular tissue changes thus providing much better information on which to assign treatment. The ultimate goal is to enable non-invasive cancer detection, staging and grading entirely through harmless imaging. 

The project will leverage the advances of a method I recently devised, called VERDICT, which uses diffusion MRI to provide an early demonstration of the power of such a model-based imaging technique in estimating cancer-tissue microstructure non-invasively. This project builds on these ideas to achieve the performance levels required to allow robust detection, grading and staging for establishing non-invasive imaging as the primary cancer diagnostic method. The project exploits advances in computational methods and in MRI technology to improve sensitivity and specificity dramatically. Specifically: 1) sophisticated optimisation techniques will enhance performance and practical utility of non-invasive model-based imaging; 2) advanced MRI sequences will allow access to new and important cancer microstructural features, such as the morphology of cell nuclei, and 3) alternative contrast methods will extend the methods to other MRI modalities beyond diffusion for complementary and additional cancer malignancy information. Although the project focuses on prostate cancer, it also aims to initiate follow-on projects to explore applications to other cancers such as brain, breast and bone metastasis.

This fellowship is a significant stepping-stone for my career in fighting cancer. My aspiration is for patients to have a quick, safe and comfortable clinical cancer examination with determinate diagnosis. Towards this vision the fellowship will allow me to capitalise on my recent progress on this idea, exploiting my current expertise in diffusion MRI, and its application in cancer. It provides me the opportunity to gain experience of leading my own multidisciplinary project and research team thus establishing myself in the UK and internationally as a leader on that topic. Moreover, the fellowship will allow me to broader my skills and collaborations to the wider medical imaging arena and variety of clinical applications in cancer. This underpins my development towards an international academic leader in the fields of computational imaging and cancer research and management.</gtr:abstractText><gtr:potentialImpactText>In spite of significant advances in diagnosis and treatment, cancer remains a major killer. Diagnosis is often inaccurate and subsequent treatment ineffective for far too many patients. Specifically prostate cancer diagnosis still relies on traditional histology via biopsies. Each year in the UK 75000 men undergo this invasive procedure, which can have unpleasant side effects and poor sensitivity, as the biopsy may miss lesions. A recent study indicates that more than 50% of prostate biopsy analyses underestimate the severity of the disease. Simultaneously biopsy can also lead to &amp;quot;over-diagnosis&amp;quot; as it can detect small clinically insignificant lesions, by random chance, which are indolent and do not need treatment. This detection of indolent disease often leads to men undergoing unnecessary radical surgery or radiotherapy. Approximately 90% of prostate cancer patients undergo such interventions, which can cause side effects like incontinence, significantly impacting their quality of life. Additionally a negative biopsy result does not imply free of cancer and negative-biopsy patients are monitored in regular repeat exams. The on-going process increases risks of side effects and is expensive for the National Health Service. Similar statistics of risks and costs translate worldwide and are also associated with other common cancers such as breast, bowel and liver.

This project develops non-intrusive imaging methods to provide diagnostic information as powerful as current invasive techniques. Primarily this will ameliorate patient suffering from the examination and the side effects, while assisting better clinical detection, staging and diagnosis by earlier and enhanced knowledge of what is happening at the tissue level. In particular improved detection rates can reduce the number of biopsies and repeated biopsies. Fewer biopsies can also decrease the cost of treatments from avoiding side effects such as urinary retention and rectal bleeding. Avoidance of biopsies will also contribute to the sustainability of the healthcare system by drastically reducing the number of surgical procedures and histopathological evaluations. Earlier cancer diagnosis can lead to more effective and potentially less radical/harmful treatments. 

The microstructure MRI methods will provide new insight into cancer biology concerning the mechanisms of tumour growth, interactions between cancer cells and healthy tissue, the role of inflammation and subtle or difficult to detect effects such as distinguishing between apoptosis and necrosis, encouraging exciting new research prospects. Further exploitation of such computational methods can lead to identification of subgroups of biological targets in the tumour that when correlated with tumour genetics could lead to the design of individualised therapies based on metabolic pathways, achieving patient stratification for precision medicine. 

The development of new MRI techniques can impact the commercial and industrial sector, such as MRI manufacturers, offering opportunities that can drive future development of medical hardware; Philips Healthcare have expressed their strong support and interest in the project. Finally microstructure imaging can also inform drug development and trials, revealing the effects of treatment earlier, moving trials more quickly to the final stages and accelerating the availability of new promising cancer treatments to patients.</gtr:potentialImpactText><gtr:fund><gtr:end>2021-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2016-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>992538</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The optimized prostate cancer imaging methods have already started to support large clinical trials for real-time decision-making.</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>F52C7727-F6FE-4344-B39A-06FF362C9760</gtr:id><gtr:impactTypes><gtr:impactType>Societal</gtr:impactType></gtr:impactTypes><gtr:outcomeId>58be98091bbde4.23229932</gtr:outcomeId><gtr:sector>Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>I developed with my group and collaborators a new computational framework to improve performance and practical utility of the current prostate cancer microstructural imaging methods (VERDICT). The new method reduces computational cost of the current VERDICT analysis and produces stable non-invasive estimates of cancer microstructure with plausible biophysical ranges. We have also made progress in testing the original VERDICT method in other cancers such as breast and brain tumours with encouraging preliminary results. I also Initiated extension of the VERDICT application remit by establishing key collaborations with clinical experts in other cancers (colorectal). Finally we developed a robust and accurate method for validating MRI prostate cancer imaging analysis methods with histology.</gtr:description><gtr:exploitationPathways>The new computational method for prostate cancer facilitates large-scale clinical applications/trials. Also the technique for histologically validating MRI analysis methods can be extended to a number of other tumours, and potentially imaging modalities.</gtr:exploitationPathways><gtr:id>B9F65D51-9287-4CD1-85CC-18E8C27FA65E</gtr:id><gtr:outcomeId>58be8ec35986b7.19899286</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We developed a mold template that contains landmark features to guide MRI scanning and guides for histological slicing. Using contours from in vivo MRI scans, the mold can be designed to hold the prostate in the in vivo position and orientation following surgical removal. This allows in vivo images to be compared with those before and after fixation, as well as histological images in the same slice plane.</gtr:description><gtr:id>CA0CAA08-FD40-45E8-8066-14F74E2817CA</gtr:id><gtr:impact>We are using this tool to validate biomarkers from diffusion MRI using corresponding histology. The device can also be applied for validation of other MRI techniques. We are consulting with the surgical and pathological teams on the use of the device to guide histological slicing and confirm patient margins. An additional EPSRC grant has been submitted on the use of machine learning techniques to relate radiological features with histological cancer grade that would benefit from this technique.</gtr:impact><gtr:outcomeId>58be8fb769d842.62716018</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>3D-printed patient-specific prostate molds</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>56751927-BD7B-4BD1-A2EE-99AF09E6584A</gtr:id><gtr:title>Limitations and Prospects for Diffusion-Weighted MRI of the Prostate.</gtr:title><gtr:parentPublicationTitle>Diagnostics (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f42f92b0f1e29e161b6713d6aa5eaf7a"><gtr:id>f42f92b0f1e29e161b6713d6aa5eaf7a</gtr:id><gtr:otherNames>Bourne R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2075-4418</gtr:issn><gtr:outcomeId>58be9ce17ebdb0.38196759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D38A7CFD-2FDF-41C0-BD52-D8731D3A441F</gtr:id><gtr:title>Apparatus for Histological Validation ofandMagnetic Resonance Imaging of the Human Prostate.</gtr:title><gtr:parentPublicationTitle>Frontiers in oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/741f85ef089ba429861c7d7417fad519"><gtr:id>741f85ef089ba429861c7d7417fad519</gtr:id><gtr:otherNames>Bourne RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2234-943X</gtr:issn><gtr:outcomeId>58d8d319148015.47262380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3124148A-F676-4D09-B9C8-46636F455148</gtr:id><gtr:title>Microstructural models for diffusion MRI in breast cancer and surrounding stroma: an ex vivo study.</gtr:title><gtr:parentPublicationTitle>NMR in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1c944ce5406cd62e7ed9dfa36e223fb"><gtr:id>b1c944ce5406cd62e7ed9dfa36e223fb</gtr:id><gtr:otherNames>Bailey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0952-3480</gtr:issn><gtr:outcomeId>5a86e24901f2f7.90580612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9A28150-7A31-4EEF-BD2F-853F902CA3AC</gtr:id><gtr:title>Measurement and modeling of diffusion time dependence of apparent diffusion coefficient and fractional anisotropy in prostate tissue ex vivo.</gtr:title><gtr:parentPublicationTitle>NMR in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f42f92b0f1e29e161b6713d6aa5eaf7a"><gtr:id>f42f92b0f1e29e161b6713d6aa5eaf7a</gtr:id><gtr:otherNames>Bourne R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0952-3480</gtr:issn><gtr:outcomeId>5a86e00cb861e3.01423041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C6654FA-170C-4373-8147-4EC20E3E7C88</gtr:id><gtr:title>Quantification of tumour microstructure in low and high-grade brain tumours using VERDICT MRI: an initial feasibility study</gtr:title><gtr:parentPublicationTitle>Neuro-Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1675327c5a6e74d4dfdeec2da99572a9"><gtr:id>1675327c5a6e74d4dfdeec2da99572a9</gtr:id><gtr:otherNames>Roberts T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a86ded29593f9.82768930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8FEE0CC-EB60-4E2F-8A5A-756D6F091CEC</gtr:id><gtr:title>Microstructure Characterization of Bone Metastases from Prostate Cancer with Diffusion MRI: Preliminary Findings</gtr:title><gtr:parentPublicationTitle>Frontiers in Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1c944ce5406cd62e7ed9dfa36e223fb"><gtr:id>b1c944ce5406cd62e7ed9dfa36e223fb</gtr:id><gtr:otherNames>Bailey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a86df0e706e81.37447492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAB9F0DB-4522-4C9E-A709-7D218531BAF3</gtr:id><gtr:title>Quantitation of brain tumour microstructure response to Temozolomide therapy using non-invasive VERDICT MRI</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1675327c5a6e74d4dfdeec2da99572a9"><gtr:id>1675327c5a6e74d4dfdeec2da99572a9</gtr:id><gtr:otherNames>Roberts T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a86e2492f01b7.71759623</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/N021967/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>16595C3C-600D-4AD2-B394-16E06F96495F</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Med.Instrument.Device&amp; Equip.</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>